
==== Front
Biomed J
Biomed J
Biomedical Journal
2319-4170
2320-2890
Chang Gung University

S2319-4170(23)00102-6
10.1016/j.bj.2023.100665
100665
Review Article
Exosomes in multiple sclerosis and Alzheimer's disease – Adversary and ally
Tang Norina ntang@pacific.edu
ab∗
a Department of Periodontics, University of the Pacific, San Francisco, USA
b Department of Laboratory Medicine, San Francisco Veterans Affairs Health Care System, San Francisco, USA
∗ Corresponding author. Department of Periodontics, University of the Pacific, 155 5th Street, San Francisco, CA 94103, USA. ntang@pacific.edu
29 9 2023
10 2024
29 9 2023
47 5 10066510 8 2023
26 9 2023
© 2023 The Authors
2023
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Neuroinflammation and the resulting neurodegeneration is a big challenge for the healthcare system, especially with the aging population. Neuroinflammation can result from a variety of insults to the central nervous system leading to an interplay between immune and brain cells that sustains chronic inflammation and injures neural cells. One facilitator of this toxic interplay are exosomes. Exosomes are nano-sized, bilayer lipid vesicles secreted by cells containing proteins, nucleic acids and lipids. Because exosomes can be internalized by other cells, their contents can elicit inflammatory responses and trigger toxicities in recipient cells. On the flip side, exosomes can act as therapeutic vehicles carrying protective cargo to maintain homeostasis. This review discusses exosome biogenesis, composition, and its role in neuroinflammation and neurodegeneration in the context of multiple sclerosis and Alzheimer's disease. The emerging roles of exosomes as biomarkers of neurologic diseases and as therapeutic delivery vehicles are also discussed. With all of these varying roles, interest and excitement in exosomes continue to grow exponentially and their promise as brain therapeutics is only beginning to be explored and harnessed.

Highlights

• Exosomes are nano-sized, bilayer lipid vesicles secreted by cells containing proteins, nucleic acids and lipids.

• Exosomes can elicit inflammation and toxicity, or act as therapeutic vehicles carrying protective cargo for homeostasis.

• As a form of liquid biopsy, exosomes can serve as biomarkers of multiple sclerosis and Alzheimer's disease.

• Exosomes can be engineered and exploited to serve as therapeutic delivery vehicles for brain diseases.

Keywords

Exosomes
Extracellular vesicles
Alzheimer's disease
Multiple sclerosis
Biomarkers
==== Body
pmcIntroduction

Neuroinflammation and the associated neurodegeneration is a big challenge for the healthcare system, especially with the aging world population. Globally, neurological diseases are the leading cause of disability and the second leading cause of mortality. It is often the case that neuroinflammation and neurodegeneration go hand-in-hand in many central nervous system (CNS) disorders. In some CNS diseases such as multiple sclerosis (MS), spinal cord injury, traumatic brain injury and stroke, inflammation is primary which then leads to secondary neurodegeneration. In other CNS diseases such as Alzheimer's disease (AD), Parkinson's disease, amyotrophic lateral sclerosis and Huntington's disease, neurodegeneration is primary, leading to secondary reactive inflammation. The prototypical CNS disease example of the former is MS while AD is the most common example of the latter.

Globally, MS affects approximately 2.8 million people as of the year 2020 [1] while AD affects roughly 40 million people as of 2019 [2]. Although there are phenotypic and neuropathologic differences between MS and AD, research studies to date suggest they are similar in that both are driven by the interplay between genetic and environmental factors that culminate in disruptions to the immune system and CNS. Many risk factors have been described for each of these diseases; however, the exact cause for each is unknown. In addition to the many genetic and environmental factors associated with these multifactorial, neurodegenerative diseases, extracellular vesicles (EVs) have recently been implicated.

EVs are small, membrane-enclosed particles secreted by cells under normal as well as pathological conditions. EVs are devoid of a nucleus and cannot replicate. EVs carry proteins, lipids and nucleic acids which reflect the state of the parental cells secreting them and when internalized, their cargo can affect the function of recipient cells. There are three major classes of EVs that are differentiated based on their method of biogenesis: microvesicles, exosomes and apoptotic bodies. Of the three, exosomes are the most widely studied. This review focuses on the role exosomes play in modulating neuroinflammation and neurodegeneration in the pathogenesis of MS and AD. In addition, the role exosomes play as potential biomarkers and therapeutics of these neurodegenerative diseases is discussed.

Exosome biogenesis

Almost all cells, both eukaryotic and prokaryotic, release EVs. EVs were first observed in 1946 as procoagulant platelet-derived particles in normal plasma. Since its discovery, EVs have been isolated from a variety of biological fluids, including blood, urine, tears, saliva, breast milk, bronchoalveolar lavage, amniotic fluid, synovial fluid, ascites, cerebrospinal fluid, bile and semen [3]. EVs were initially simply thought of as “garbage cans” into which unwanted materials were thrown into, that are then released from the cells. However, evidence in the past decade indicates that EVs are signaling vessels delivering cell-specific cargos of proteins, lipids and nucleic acids to other cells where they can alter function and physiology.

EVs can be generally divided into three main classes depending on their origins: apoptotic bodies, microvesicles and exosomes [4]. Apoptotic bodies are blebs from the plasma membrane of apoptotic cells with sizes ranging from ∼100 to 5000 nm. Microvesicles are smaller, ∼100–1000 nm, and bud directly from the plasma membrane of living cells. Exosomes are the smallest of the three, at ∼50–150 nm in size. In contrast to the other two EV classes, exosomes are formed by the inward invagination of endosomal membranes, giving rise to multivesicular bodies (MVBs) that either fuse with lysosomes or fuse with the plasma membrane. When fused with the plasma membrane, MVBs release their intraluminal vesicles (ILVs) into the extracellular milieu via exocytosis where they then are called exosomes [Fig. 1].Fig. 1 Extracellular vesicle (EV) classes, origins and characteristics. The three major classes of EVs are depicted based on their origins. Microvesicles and apoptotic bodies are generated via budding and blebbing of the plasma membrane, respectively. Exosomes are generated via the endocytic pathway by exocytosis of the intraluminal vesicles of multivesicular bodies that fuse with the plasma membrane. EV size [4], appearance by electron microscopy [85], sedimentation [85], and density [4] are shown. Proteins, lipids and nucleic acids frequently found in exosomes, which largely reflect their endocytic origin, along with some cell-specific molecules are illustrated. Abbreviations: ALIX: ALG-2-interacting protein X; β-gal:β-galactosidase;CCL2:chemokine (C–C motif) ligand 2;GAPDH:glyceraldehyde-3-phosphate dehydrogenase;Hsp:heat shock protein; ICAM-1:intercellular adhesion molecule 1; IL-1β:interleukin 1β; MHC:major histocompatibility complex; miR:microRNA; ncRNA:non-coding RNA; (P)RR:(pro)renin receptor; PYK:pyruvate kinase; Rabs:Ras-associated binding proteins; SNARE:soluble N-ethylmaleimide-sensitive fusion attachment protein receptor; TfR:transferrin receptor; TGF-β: transforming growth factor β; TNF-α: tumor necrosis factor α; TNFR: tumor necrosis factor receptor; TSG101: tumor susceptibility gene 101.

Fig. 1

Exosome composition

During its formation, the multivesicular endosomes take up bits of the cytoplasm and its contents, becoming part of the exosome. Thus, exosomal cargo reflects the identity and real time physiologic state of the parental secreting cell. There is no one single marker that can uniquely identify exosomes or other subpopulations of EVs. Nevertheless, specific proteins have been identified that are enriched in exosomes that reflect their biogenesis [Fig. 1]. These include tetraspanin proteins (CD9, CD63, and CD81) present in the endosomal membrane, endosomal sorting complex required for transport (ESCRT) proteins (ALIX and TSG101) that regulate cargo targeting into and the formation of ILVs, proteins required for membrane transport and fusion (annexins, Rabs, flotillins, SNAREs), heat shock proteins (Hsp70, Hsp90) that help recruit cytosolic components, membrane lipids (cholesterol, sphingomyelin, ceramides, glycerophospholipids), cytoskeletal proteins (actin, tubulin, cofilin), major histocompatibility complex (MHC) I proteins, integrins, and mitochondrial proteins [3]. A variety of glycoproteins as well as cell type-specific exosomal proteins, such as MHC II molecules from antigen presenting cells, have also been described [3,5]. In addition to proteins and lipids, exosomes also contain nucleic acids: DNA, mRNA, microRNA (miR), non-coding RNA (ncRNA) and other small RNA species [3]. Small ncRNAs ranging in length from 4 to 40 nucleotides, such as miRs, are particularly enriched, with exosomal miRs having a different profile than parental cells due to active sorting [3]. [Table 1] lists examples of molecules reported in exosomes. There are also public online databases such as ExoCarta (www.exocarta.org), vesiclepedia (www.microvesicles.org) and EVpedia (www.evpedia.info) that are dynamically cataloging the many different components found in exosomes and other EVs.Table 1 Exosome composition.

Table 1Class	Examples	
Proteins	
 Tetraspanins	CD9, CD63, CD81	
 ESCRT machinery	ALIX, TSG-101	
 Membrane transport and fusion	annexins, flotillins, Rabs, SNAREs	
 Heat shock	Hsp70, Hsp90	
 Cytoskeleton	actin, cofilin, tubulin	
 Mitochondrial proteins	humanin, citrate synthase	
 Major histocompatibility complex	MHC I, MHC II	
 Adhesion	ICAM-1, integrin-α, -β, P-selectin	
 Glycoproteins	β-gal, glycans	
 Growth factors and cytokines	CCL2, FasL, IL-1β, TGF-β, TNF-α, TRAIL	
 Receptors	EGFR, TfR, TNFR	
Nucleic Acids	
 DNA	Braf, Egfr, mtDNA	
 mRNA	Icam-1, Il-6, Tnf	
 miR	miR-150, miR-320, miR-451	
 ncRNA	LncRNA, rRNA, tRNA, snRNA	
Lipids	
 Steroids	cholesterol, sex hormones	
 Sphingolipids	ceramides, sphingomyelin, gangliosides	
 Glycerophospholipids	PS, PC, PE, PI	
Abbreviations: Braf:b-raf protooncogene; Egfr:epidermal growth factor; FasL:Fas ligand; LncRNA:long non-coding RNA; mtDNA:mitochondrial DNA; PC:phosphatidylcholine; PE:phosphatidylethanolamine; PI:phosphatidylinositol;PS: phosphatidylserine; snRNA:small nuclear RNA; TRAIL:TNF-related apoptosis inducing ligand.

Exosome sample purity and nomenclature

Because EVs are heterogeneous in size and composition with physical characteristics that overlap with other particles, it is very difficult to purify a homogeneous population of EVs that is derived from one EV class and from a single cell type that is devoid of co-isolated contaminants such as protein aggregates and lipid-rich particles. Many of the studies referred to in this review article describe purified “exosome” samples which, in reality, are mixtures of microparticles from heterogeneous origins. The same holds true for studies on microvesicles and other microparticles. Given the difficulty in isolating one class of EVs (for example, exosomes) without co-isolating another class (such as microvesicles) due to their overlapping size, density and other physical characteristics, the International Society of Extracellular Vesicles (ISEV) in 2018 published a position statement endorsing the use of the generic term “EV” over the use of any specific EV term when referring to lipid bi-layer-enclosed particles naturally released from cells that do not contain a functional nucleus [6]. In keeping with the ISEV guidelines, this review uses the term “EV” unless otherwise stated by the original source publication. However, the reader should keep in mind that, despite its name/label, all EV samples studied to date are heterogeneous mixtures of microparticles containing multiple EV classes with co-isolated protein and lipid contaminants. Depending on the method of isolation, the microparticle sample may be enriched for a specific EV class and/or cellular origin.

Extracellular vesicles in neuroinflammation and neurodegenerative diseases

Different cells release different EVs which play different roles at different times depending on the physiologic state. Owing to their biological characteristics, exosomes/EVs can spread around in the CNS passing from one cell to another, bringing along signaling molecules [7]. In health, the immune system and CNS EVs contribute to myelination, trophic support, synaptic plasticity, and antigen presentation of neurons [[8], [9], [10]]. They can also cross the blood brain barrier (BBB) diffusing into peripheral blood to reach other organs, and vice versa with peripheral EVs crossing the BBB to reach the CNS [11]. In disease, EVs in the CNS (whether originating from CNS cells or those that have crossed the BBB from the periphery) can carry oxidative, inflammatory, amyloidogenic, and other damaging molecules that contribute to neuroinflammation and neurodegeneration [11].

Multiple sclerosis pathogenesis

Multiple sclerosis is a multifactorial, demyelinating disease of the CNS. It is the most common disabling neurological disease of young adults with symptom onset generally occurring between the ages of 20–40 years. It is more common in females than males (3:1 ratio). The disease is characterized by immune system activation, BBB disruption, focal lymphocytic infiltrates, breakdown of myelin sheaths, astrogliosis, microglia activation, and neuronal degeneration. There are four types of MS, listed in order of generally increasing disability or disease severity: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS). Each type follows a different disease course and can be further categorized into active or inactive disease depending on whether the condition is progressing at the time. The pathologies seen in MS are a result of multiple inflammatory processes taking place in the periphery, BBB and CNS parenchyma involving a variety of cells --- including immune, endothelial, and CNS cells. All of these cells interact to facilitate the development of MS with EVs participating in some of these interactions [Fig. 2].Fig. 2 EV involvement in multiple sclerosis and Alzheimer's disease. Different cells release different EVs which play varying roles depending on the physiologic state of the secreting cell. During disease, EVs carry biomolecules that facilitate neuroinflammation, neurodegeneration and disrupt the BBB. In health, EVs carry biomolecules that help maintain tissue homeostasis and neurovasculature integrity. Because EVs cross the BBB, EVs derived from MSCs or those specifically engineered to encapsulate therapeutic cargo can enter the CNS to help remyelinate and regenerate neurons.

Fig. 2

An early event in the development of MS lesions is peripheral immune activation and the disruption of the BBB. Primed peripheral lymphocytes mount a reaction against CNS epitopes, including oligodendrocyte proteins such as myelin basic protein (MBP), proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG). Once activated, these peripheral immune cells (lymphocytes and other leukocytes) release a cascade of cytokines that damage the BBB, allowing leukocyte transmigration and entry into the CNS. While in the CNS, the inflammatory cytokines produced by the leukocytes damage the myelin sheath and injure their parent cells, the oligodendrocytes. In reaction to the damage, reactive gliosis (also known as glial scarring) occurs whereby oligodendrocyte precursor cells, stem cells, microglia and astrocytes are recruited to the site of demyelination where they undergo cellular changes, including activation and cell division. These cellular changes, in coordination with one another, can ultimately lead to the formation of the final glial scar, which consists of a meshwork of tightly interwoven astrocyte processes surrounded by extracellular matrix. A consequence of reactive gliosis and formation of glial scar is failure to regenerate and remyelinate the axons, leading to neurodegeneration.

Extracellular vesicles in MS pathogenesis

Accumulating evidence implicates EVs released by immune cells, endothelial cells and CNS cells in multiple steps of the MS disease process [Table 2]. With regard to autoreactive T cells, it was shown that miR-326 can induce autoreactive Th17 cell differentiation [12]. This, together with a later study that found increased expression of miR-326 in exosomes derived from conventional T cells of patients with RRMS [13] suggests that T cell exosomes and their miR-326 cargo may promote autoreactivity in MS disease.Table 2 Multiple sclerosis studies with EVs (selected publications).

Table 2	EV Source	EV Component	Effect/Finding	Reference	
Pathogenesis	Blood T cell exosomes	miR-326a	Autoreactivity: ↑ Th17 differentiation	[12,13]	
Blood B cells	Exosomes from B cells of MS patients	↓ Myelination: Induce oligodendrocyte death	[19]	
Plasma Endothelial cells	Plasma CD31+ microparticles (<1.5 mm size)	BBB disruption: ↑ # of plasma microparticles during exacerbation vs remission phase and HC, which positively correlated to gadolinium-enhancing lesions seen on MRI (an indicator of BBB disruption)	[14]	
Endothelial cells (TNFα-treated)	CD54+ brain endothelial cell microparticles	BBB disruption & transmigration: 1) In vitro studies showed binding, activation and ↑ transmigration of monocytes. 2) ↑ endothelial microparticles in exacerbation vs remission phase of MS.	[15]	
Plasma Endothelial cells	Microparticles (<1.5 mm in size)	BBB disruption & transmigration: Plasma from RRMS patients in exacerbation ↑ # of endothelial microparticles and ↑ monocyte transmigration vs plasma from remission patients and HC.	[16]	
Plasma Platelets & Endothelial Cells	Plasma microparticles (<3 mm size)	BBB disruption: 1) Plasma EVs derived from platelets and endothelial cells were ↑ in all forms of MS (CIS, RRMS, SPMS, PPMS) vs HC. 2) ↑ permeability of endothelial monolayer.	[47]	
CSF Myeloid Cells (Microglia/Macrophage)	CSF microvesicles	↑ inflammation: 1) ↑ Myeloid microvesicle concentration in CSF of EAE mice, CIS and relapsing RRMS patients. 2) Myeloid microvesicles spread inflammatory signals in vitro and in vivo.	[27]	
Plasma exosomes	miR-let-7i	↑ inflammation: Suppressed induction of Treg cells by targeting insulin like growth factor 1 receptor and transforming growth factor beta receptor 1.	[86]	
Astrocytic EVs	Complement proteins (C1q, C3, C3b/iC3b, C4, C5, C5a, Factor H)	↑ synaptic loss: Increased complement proteins in CSF astrocytic EVs of MS vs HC.	[87]	
Plasma EVs	Fibrinogen	Demyelination: 1) Mouse plasma EVs containing fibrinogen injected into EAE mice induced CD8+ T cells and spontaneous relapse. 2) Fibrinogen was also found in human plasma EVs from MS patients.	[21]	
Serum exosomes	MOG	Autoreactivity: 1) ↑ serum exosomal MOG which correlated with gadolinium+ brain lesions. 2) Exosomes from RRMS and SPMS induced ↑ MOG-TCR T cell proliferation vs HC.	[88]	
Biomarkers	Plasma T cells, B cells, and monocytes	Plasma EVs	Plasma EVs from these cell types were ↑ in untreated RRMS vs HC	[48]	
Plasma endothelial EVs (0.2–1 mm)		Diagnose active MS: ↑ # of plasma endothelial EVs in active RRMS vs HC and RRMS stable disease	[46]	
Serum oligodendrocyte EVs	MBP	Diagnose and differentiate different MS types: Serum oligodendrocyte EVs from MS patients (CIS, RRMS, PPMS) had ↑ MBP concentration compared to HC, which correlated with disease activity.	[51]	
CSF myeloid EVs	CSF myeloid EVs (≤1 mm in size)	Differentiate between progressive MS and CIS: 1) ↑ # of CSF EVs in progressive MS vs CIS. 2) Lesions correlated with ↑ CSF EVs from memory T cells, Th1 cells and Th2 cells.	[49]	
Serum exosomes	Epstein-Barr viral proteins (EBNA1, LMP1, LMP2A)	Diagnose RRMS: 1) ↑ Epstein-Barr viral proteins in RRMS vs HC. 2) EBV+ exosomes induced inflammatory response in monocyte-derived macrophages.	[52]	
Serum exosomes	miR-15b-5p, miR-451a, miR-30b-5p, miR-342-3p	Diagnose RRMS: These miRs were ↑ regulated in RRMS vs HC.	[50]	
Serum exosomes	miR-127-3p, miR-370-3p, miR-409-3p, miR-432-5p	Diagnose SPMS: These miRs were ↑ regulated in SPMS vs HC.	[50]	
Serum exosomes	miR-15b-5p, miR-23a-3p, miR-223-3p, miR-374a-5p, miR-30b-5p, miR-433-3p, miR-485-3p, miR-342-3p, miR-432-5p	Differentiate between RRMS and SPMS: These miRs were ↑ regulated in RRMS vs SPMS.	[50]	
Serum Exosomes	miR-122-5p, miR-196b-5p, miR-301a-3p, miR-532-5p	Diagnose RRMS: These miRs were ↓ regulated in RRMS vs HC.	[89]	
	EV Source	Target	Effect/Finding	Reference	
Therapeutics	Human adipose MSCs	↓ glial fibrillary acidic protein and Iba-1 in brain. ↑MBP.	Improved motor deficits, ↓ brain atrophy and ↑ remyelination in Theiler's murine encephalomyelitis virus-induced demyelinating disease, a mouse model of MS	[90]	
Human bone marrow MSCs stimulated by IFNγ	↓ proinflammatory Th1 and Th17 cytokines (IL-6, IL-12p-70, IL-17AF, IL-22). ↑ immunosuppressive cytokine indoleamine 2,3 dioxygenase	Improved clinical score, ↓ demyelination, ↓ neuroinflammation, and ↑ # of Treg cells in EAE mice.	[91]	
Rat bone marrow MSCs	Regulate microglia polarization	↓ neural behavioral scores, inflammatory cell infiltration, neuroinflammation (↑ IL-10 and TGF-β and ↓ TNF-α and IL-12), and demyelination in EAE rat model.	[92]	
Human placental MSCs	↓ DNA damage in oligodendrocytes	Myelin regeneration: In vivo improvement in motor function and ↑ myelination in spinal cord. In vitro induction of OPC differentiation into mature myelinating oligodendrocytes.	[93]	
Human umbilical cord MSCs	↓ pro-inflammatory cytokines (IL-17a, TNF-α, and IFN-γ), ↑ anti-inflammatory cytokines (IL-4, IL-10)	Attenuate EAE: Improve clinical score, ↓ pro-inflammatory cytokines (IL-17a, TNF-α, and IFN-γ), ↑ anti-inflammatory cytokines (IL-4, IL-10), ↓ leukocyte infiltration in EAE mice.	[94]	
Mouse oligodendrocyte EVs containing MBP, MOG and PLP	Induce immunosuppressive monocytes and apoptosis of autoreactive CD4+ T cells.	↓ EAE pathophysiology in several EAE models by restoring immune tolerance thru 1) induction of immunosuppressive monocytes, and 2) apoptosis of CD4+ T cells.	[95]	
Engineered mouse microglial EVs containing IL-4 plasmid	↑ anti-inflammatory mRNA markers (ym1, arg1) in phagocytic cells.	↓ neuroinflammation and EAE pathophysiology.	[79]	
Engineered HEK 293T cell EVs overexpressing miR-219a-5p	Induce OPC differentiation	Myelin regeneration and clinical score improvement in EAE mice.	[80]	
Engineered EL-4 mouse lymphoma cell-derived exosomes exogenously loaded with curcumin	Anti-inflammation	↓ MOG-induced EAE pathophysiology: Exosome encapsulated curcumin inhibits LPS-induced brain inflammation and myelin oligodendrocyte glycoprotein (MOG) induced autoimmune responses in an EAE model.	[76]	
Engineered mouse macrophage RAW264.7 cell-derived exosomes exogenously loaded with resveratrol (RSV-Exo)	Anti-inflammation (reduce microglia and NF-κB activation)	↓ EAE pathophysiology: In mouse EAE model of MS, intranasal administration of RSV-Exo 1) ↓ inflammatory cytokines (TGF-β, IFN-γ, IL-1β, IL-6, IL-17) and ↑ anti-inflammatory cytokine IL-10 in the brain, spinal cord, spleen and blood. 2) ↓ Iba-1 and NF-κB expression in the brain, spinal cord and spleen. 3) ↓ inflammatory cell infiltration into the brain and spinal cord. 4) ↓ demyelination in the spinal cord.	[78]	
Abbreviations: arg1:arginase-1;CIS:clinically isolated syndrome;EAE:experimental autoimmune encephalomyelitis;HC:healthy control;Iba-1:ionized calcium binding adaptor molecule 1;MBP:myelin basic protein;MOG:myelin oligodendrocyte glycoprotein;PLP:proteolipid protein;PPMS:primary progressive multiple sclerosis;RRMS:relapsing remitting multiple sclerosis;SPMS:secondary progressive multiple sclerosis;ym1:chitinase 3-like 3.

The majority of MS lesions occur near disrupted blood vessels and EVs may play a role here by increasing BBB permeability and allowing leukocyte transmigration into the CNS. In a series of experiments by one research group, higher concentrations of microparticles/EVs in the plasma of MS patients in exacerbation versus (vs) those in remission or vs healthy controls (HCs) were found, with the plasma microparticle concentration correlating to gadolinium-enhancing lesions seen on MRI, an indicator of BBB disruption [14]. Later, it was identified that the population of plasma microparticles that were increased in MS were derived from endothelial cells and in vitro experiments demonstrated that endothelial cells activated with tumor necrosis factor-alpha (TNF-α) released microparticles that bound, activated and enhanced the transmigration of monocytes across an endothelial cell layer [15]. A year later, the in vivo significance was demonstrated when this group published that plasma from RRMS patients in exacerbation increased monocyte transmigration vs plasma from RRMS patients in remission or control plasma, and this transmigration was further increased when the monocytes were treated with microparticles derived from TNF-α-treated endothelial cells [16]. This series of studies implicate endothelial cell EVs in the BBB disruption and the resultant monocyte transmigration pathologies seen in MS disease. Fueling the increased BBB permeability brought on by the endothelial EVs, caspase-1 contained in monocyte microvesicles can injure vascular smooth muscle cells [17], thereby degrading the neurovascular unit and furthering entry of immune cells into the CNS. In addition to monocytes and T cells, the disruption of the BBB may allow entry of B cells [18] that release exosomes capable of inducing oligodendrocyte death, leading to the reduced myelination seen in MS lesions [19]. The disruption in the BBB not only allows infiltration of immune cells but also entry of specific blood factors encapsulated in EVs into the CNS that can promote lesion formation. For example, injection of the blood coagulation protein fibrinogen into mice with disrupted BBB stimulated the recruitment and activation of myelin antigen-specific Th1 cells and peripheral monocytes, leading to encephalitogenic adaptive immune responses and demyelination [20]. Recently, it was found that mouse plasma EVs containing fibrinogen can induce CD8+ T cells and spontaneous relapse when injected into mice with experimental autoimmune encephalomyelitis (EAE), a mouse model for MS [21].

After gaining entry into the CNS, the activated immune cells can release a cascade of inflammatory cytokines into the extracellular milieu that activate CNS cells. The activated CNS cells in turn release proinflammatory cytokines, chemokines, reactive oxygen species and other toxic molecules that mediate neuroinflammation-induced neurodegeneration [22]. One important mechanism of tissue injury in MS is the oxidative damage mediated by activated macrophages and microglia that results in mitochondrial injury responsible for many of the essential pathological features of MS lesions: demyelination, oligodendrocyte apoptosis, axonal degeneration, and structural and functional disturbances of astrocytes and oligodendrocyte progenitor cells [23].

In addition to the above deleterious molecules, activated CNS cells can release EVs to potentiate the neuroinflammation and neurodegeneration seen in MS. For example, reactive astrocytes can secrete microvesicles containing MMPs [24] to further disrupt the BBB and fuel neuroinflammation. Activated macrophages that have trafficked into the brain as well as resident microglia can release extracellular vesicles that contain IL-1β [25], major histocompatibility complex class II (MHC II) molecules [26], and other cargo that further spread inflammatory signals [27]. Indeed, it has been found that myeloid microvesicle concentrations were increased in the cerebral spinal fluids (CSF) of not only relapsing and remitting EAE mice, but also in CIS and relapsing RRMS patients [27].

These studies provide just a sampling of the variety of ways by which EVs can participate in MS pathogenesis. For a more in-depth discussion, the reader is directed to another recent review [28].

Alzheimer's disease pathogenesis

Alzheimer's disease is the most common neurodegenerative disease manifesting in dementia and is typically a disease of old age. AD is characterized by progressive impairment in cognition, mental state, and ability to carry out daily life activities. The main histopathological features of AD are the accumulation of extracellular neuritic plaques and intracellular neurofibrillary tangles (NFTs), which lead to neuronal cell death and secondary reactive neuroinflammation. AD plaques are spherical microscopic lesions consisting of a core of amyloid beta (Aβ)-peptide surrounded by enlarged axonal endings. Aβ peptides are derived from the proteolytic cleavage of amyloid precursor protein (APP) by a family of enzymes (γ-secretases and β-secretases) that include presenilin 1 and presenilin 2. They are typically 36–43 amino acids long and can self-assemble into oligomers and fibrils that are toxic to neurons. The predominant Aβ fragments found in amyloid deposits are Aβ40 and Aβ42, which have 40 and 42 residues, respectively. Although cleavage of APP by β- and γ-secretases produce pathologic Aβ fragments, cleavage of APP by α-secretase produces soluble peptides that are non-amyloidogenic, neuroprotective and neurotrophic. Multiple mechanisms of toxicity have been attributed to Aβ oligomers, including activation of inflammation, induction of oxidative stress, disruption of membrane receptor functions, formation of membrane pores and alteration of ionic homeostasis across the membrane, and modification of DNA structure [29]. NFTs are formed by aggregates of hyperphosphorylated, tubulin-associated unit (pTau) proteins and can be seen as fibrillary, cytoplasmic structures inside neurons. NFTs cause neuronal dysfunction and death by destabilizing the microtubule network thereby affecting axonal transport. In addition to Aβ plaques and NFTs, synaptic damage and loss are significant features of AD that best correlate with cognitive decline [30]. It is thought that misfolded Aβ and Tau proteins facilitate AD pathology by acting as templates on which healthy proteins misfold and grow into increasingly larger aggregates, and spreading in a prion-like manner [31]. In addition, aggregation of pTau and Aβ activates microglia and astrocytes, triggering an innate immune response that spreads across the brain, leading to the release of inflammatory molecules that contribute to AD progression and severity [32].

Extracellular vesicles in AD pathogenesis

Although the etiology of AD is unknown, one leading hypothesis is an imbalance between neuronal production of Aβ and extracellular clearance that leads to protein misfolding, aggregation and accumulation in plaques. Evidence indicates that EVs participate in this balance as players on both sides: degradation and formation of amyloid plaques. As early as 2002, Aβ peptides were found in MVBs of normal neurons and more so in AD neurons [33]. In 2006, it was shown that Aβ was secreted extracellularly by neurons in association with exosomes, and the exosomal marker ALIX was enriched around neuritic plaques of AD brains [34]. Then in 2014, it was found that astrocyte exosomes, when co-incubated with Aβ42, induced Aβ aggregation and blocked uptake by glial cells in vitro. Moreover, inhibition of exosome secretion by neutral sphingomyelinase 2 inhibitor GW4869 resulted in lower Aβ42 levels and plaque burden in 5XFAD mouse brains, a murine model for AD [35]. In this same year, another group reported that when exposed to Aβ, microglia released microvesicles that were toxic to neurons in vitro [36]. In addition, microvesicles isolated from the CSF of AD patients showed increased Aβ bound to neurites and increased neuronal cell toxicity. These data suggest that pathologic Aβ can be encapsulated in exosomes and released by various CNS cells into the extracellular milieu to form plaque.

In contrast to these observations for EVs' role in extracellular Aβ accumulation and neuronal toxicity, there is also evidence supporting their role in amyloid degradation and neuronal health. For instance, it was shown in vitro that not only can mouse neuronal exosomes (derived from N2a neuroblastoma cells and from primary cortical neurons) bind to soluble amyloid peptides to prevent their toxic aggregation but mouse N2a neuroblastoma exosomes also facilitated Aβ internalization into microglia for degradation [37]. Later, this same group showed that these neuronal exosomes carried glycosphingolipids essential for Aβ binding and injection of these neuronal exosomes into the brains of APP transgenic mice (a mouse model for AD) reduced Aβ and amyloid depositions [38,39]. By sequestering Aβ, not only can neuronal exosomes deliver this toxic material to microglia for degradation, but they can also neutralize Aβ′s toxic effects on synaptic plasticity [40]. It is unclear whether the seemingly opposing roles of EVs are due to limitations in EV sample purity and reproducibility across laboratories, or a reflection of the variable nature of EVs whose cargo changes dynamically to reflect the temporal and physiologic state of the secreting cell.

In addition to Aβ, exosomes/EVs from different cell types have been shown to contain and affect phosphorylated Tau protein homeostasis. For example, when compared to cognitively normal subjects, plasma neuronal EV levels of pTau-181 and pTau-396 were not only higher in the AD patients but when these neuronal EVs were injected into wildtype mouse brains, greater pathologic pTau protein levels were observed, suggesting that neuronal EVs can seed and propagate Tau pathology onto normal brains [41]. For microglial EVs, Asai and colleagues showed that they can also carry and spread Tau [42]. Specifically, when treated with human Tau oligomers, cultured primary mouse microglial cells phagocytosed and secreted the Tau proteins in exosomes. In addition, deleting microglia from mouse brains led to reduced Tau propagation from the entorhinal cortex to the dentate gyrus regions of the brain. Finally, in vitro inhibition of specific exosome secretion by microglia resulted in reduced Tau transmission to neurons while in vivo general inhibition of exosome secretion led to reduced pTau in mouse brains. For astroglial EVs, it was shown that when exposed to Aβ, human cortical astrocytes produced more of the pTau species associated with NFTs and released them within exosomes [43]. More recently, an in vivo study of AD brains shows the presence of pTau species in astrocytes of the dentate gyrus which correlated with Braak stage severity, and overexpression of the 3R Tau isoform in mouse dentate gyrus astrocytes led to neuronal disruptions and spatial memory impairment [44]. Interestingly, the 3R Tau inclusions seen in this study were not only higher in AD individuals but exacerbated in those with amyloid plaques. Together, these studies suggest that the loss of Tau homeostasis in astrocytes can contribute to AD-like symptoms and astrocytic EVs containing pTau may contribute to that imbalance. Further implicating and, perhaps, emphasizing the role of EVs in Tau spread, it was observed that neuronal uptake of Tau in vivo was shown to be higher when Tau is encapsulated in exosomes vs its naked form when injected into mouse brains [42].

Much of the work on EVs in AD has focused on their role as vehicles for Aβ and Tau spread. However, EVs have also been shown to participate in other cellular mechanisms found disrupted in AD, such as impaired lysosome degradation, neuroinflammation, BBB disruption, synaptic dysfunction, and diminished neuroprotection [Fig. 2] [Table 3]. For information on EV roles in these other mechanisms, see the recent review by Gomes and colleagues [45].Table 3 Alzheimer's disease studies with EVs (selected publications).

Table 3	EV Source	EV Component	Effect/Finding	Reference	
Pathogenesis	HeLa (human epithelial), N2a (mouse neuroblastoma) exosomes	Aβ	Aβ propagation: 1) These cells release exosomes containing Aβ. 2) ALIX was enriched around neuritic plaques of AD brains.	[34]	
Neuronal exosomes from AD brain	Aβ	Aβ propagation between neurons and neuronal toxicity: 1) Exosomes from AD brains have increased Aβ. 2) These exosomes were internalized by neuronal cultures, resulting in cytotoxicity.	[54]	
Plasma neuronal EVs	pTau-181, pTau-396, Aβ42	pTau seeding and propagation: 1) pTau-181, pTau-396 and Aβ42 were all higher in AD. Neurogranin and REST were lower in AD. 2) Mice brains injected with plasma nEVs from AD patients showed ↑ pTau in brain tissue.	[41]	
Plasma neuronal EVs	ratio of P-serine-IRS-1 to P-tyrosine-IRS-1	Insulin resistance: 1) ↑ P-serine-IRS-1 and ↓ P-tyrosine-IRS-1 in AD vs matched controls. 2) These changes in phosphorylated IRS-1 were seen in preclinical AD and plateaued as early as 10 years before clinical diagnosis of manifest AD.	[64]	
Microglial microvesicles	Aβ40, Aβ42	Neuronal toxicity: 1) Aβ42-treated microglia released microvesicles which contained Aβ42 and Aβ40. 2) CSF myeloid microvesicle number was ↑ in AD vs HC. 3) Neurons incubated with microvesicles derived from CSF of AD patients showed increased Aβ bound to dendrites and increased neuronal cell death.	[36]	
Mouse microglial EVs	Aβ42	Aβ propagation between neurons and synaptic dysfunction: Aβ42-treated mouse microglia release EVs containing Aβ42 which 1) alters dendritic spine morphology in vitro, and 2) when injected into mouse brains, causes synaptic dysfunction by impairing low-term potentiation in the entorhinal cortex which then spreads to the dentate gyrus.	[57]	
Primary cultured murine microglial exosomes	Tau	Tau spread to neurons: 1) mouse microglia phagocytosed and secreted Tau in exosomes. 2) Mice depleted of microglia had 47% and 70% reductions in pTau in the entorhinal cortex and dentate gyrus, respectively.	[42]	
Mouse microglial EVs	pTau	Tau propagation: 1) Microglia depletion in mouse brains ↓ pTau propagation, and ↑ plaque burden and plaque-associated pTau+ dystrophic neurites. 2) Neurodegenerative/Mac2+ microglia, released >3 times more EVs than homeostatic/Mac2- microglia in humanized APP mutant knock-in (AppNL-G-F) mice.	[56]	
Microglial EVs from early AD mouse brain	glutaminase C (GAC)	Neuroinflammation thru microglial activation: 1) GAC protein level is higher in APP/PS1 mouse brains vs control mice. 2) In vitro plasmid-transfected mouse microglia overexpressing GAC shifted to a proinflammatory state and released more exosomes containing proinflammatory miRs (miR-155, miR-130, miR-145a, miR-23b, miR-146a & others).	[60]	
Primary human cortical astrocytic exosomes	Tau and pTau	Tau propagation: Aβ-treated astrocytes have increased intracellular pTau which are secreted in association with exosomes.	[43]	
Plasma astrocytic EVs	IL-6, TNF-α, IL-1β, complement proteins (C1q, C4b, C3d, factor B, factor D, Bb, C3b, MAC)	Neuroinflammation and neuronal damage in late AD: 1) IL-6, TNF-α, IL-1β and complement effector proteins (C1q, C4b, C3d, factor B, factor D, Bb, C3b, MAC) were ↑ in AD vs cognitively normal controls while complement regulatory proteins (CD59, CD46, decay-accelerating factor (DAF) and complement receptor type 1 (CR1)) were ↓. 2) Complement protein levels correlated with severity of disease.	[58]	
Astrocytic EVs from AD brains	aquaporin 4 (AQP4)	BBB disruption: 1) Injection of astrocytic EVs isolated from postmortem familial AD & sporadic AD brains into mice induced perivascular astrocyte reactivity and reduced blood vessel integrity. 2) 3xTg-AD mice astrocytes released more EVs vs control mice.	[62]	
	AD brain-derived EVs	Tau oligomers	pTau seeding and propagation: 1) Alzheimer's disease extracellular vesicles had ↑ pathologic/PHF1+ pTau and were more efﬁciently internalized by murine cortical neurons. 2) These AD-EVs were more capable of misfolding and transferring Tau in vitro vs prodromal AD/MCI and control EVs. 3) Inoculation of AD brain-derived EVs resulted in the accumulation of abnormally phosphorylated Tau throughout the hippocampus	[96]	
Biomarkers	Plasma neuronal EVs from AD patients	pTau-181, pTau-396, Aβ42	Preclinical diagnosis: 1) pTau-181, pTau-396 and Aβ42 were all elevated in AD. 2) These neuronal EV biomarkers were also elevated 10 years before symptom onset and at the time of diagnosis.	[53]	
Plasma neuronal EVs from AD patients	Increased levels of pTau (pTau-181, pTau-231), Aβ42 and pIRS-1	Preclinical diagnosis: In a large case-control study, combining these neuronal EV biomarkers predicted AD about 4 years before symptom onset. Also, individual biomarkers were associated with cognitive performance.	[55]	
Plasma neuronal exosomes	cathepsin D, LAMP-1, ubiquitin, Hsp70	Preclinical diagnosis and monitor disease progression: 1) AD patients had higher exosomal levels of cathepsin D, LAMP-1 and ubiquitin proteins, and lower exosomal levels of Hsp70. 2) These 4 protein changes were evident up to 10 years before clinical onset. 3) Compared to FTD, AD had higher cathepsin D, LAMP-1 and ubiquitin.	[61]	
Plasma neuronal exosomes from AD patients	presynaptic proteins (NRXN2a, NLGN1, AMPA4 receptor)	Preclinical diagnosis and monitor disease progression: ↓ presynaptic proteins (NRXN2a, NLGN1, AMPA4 receptor) in preclinical period 6–11 years before the onset of dementia vs matched controls, which declined progressively with dementia development. 2) ↓ presynaptic proteins (NLGN1, AMPA4 receptor) in AD vs Controls, which inversely correlated with ADAS cognition score.	[71]	
Plasma neuronal exosomes	synaptic proteins (GAP43, neurogranin, SNAP25, and synaptotagmin 1)	Preclinical diagnosis and monitor disease progression: ↓ GAP43, neurogranin, SNAP25, and synaptotagmin 1 in AD vs Controls, which correlated with disease severity and MMSE scores (i.e., levels are lowest in AD, then aMCI, then Controls). 2) Combination of these four synaptic proteins can predict AD-associated cognitive impairment 5–7 years before appearance of symptoms (Area Under the Curve = 0.89).	[74]	
CD11b+ microglial EVs (<200 nm in size)	FTH1, TREM2, Tau	Diagnose AD: Loss of homeostatic microglia: 1) ↑ Tau and disease associated microglia markers (FTH1 and TREM2) in AD vs normal controls. 2) ↓ microglia homeostatic markers (P2RY12, TMEM119) in AD vs normal Controls.	[66]	
AD brain-derived astrocytic EVs	integrin-β1 (ITGB1)	Diagnose AD: ↑ integrin-β1 in AD brain samples, which correlated with AD hallmarks (Aβ42, total Tau and pTau-396)	[67]	
Plasma astrocyte exosomes	complement proteins	Monitor disease progression: ADE levels of complement proteins (C1q, C4b, factor D, fragment Bb, C5b, C3b, and C5b-C9) were ↑ in patients with MCIC (MCI converting to dementia within 3 years) vs MCIS (MCI stable). ADE levels of inhibitory complement proteins (decay-accelerating factor, CD46, CD59, and type 1 complement receptor) were ↓ in MCIC vs MCIS.	[72]	
Brain fluid-derived EVs	pathological Tau species	Differentiate AD tauopathy from other tauopathies: Brain fluid-derived EVs isolated from AD brain tissues contained Tau which, when injected into THY-tau30 mouse brains, induced Tau phosphorylation and conformational changes in AD vs non-demented controls, progressive supranuclear palsy (PSP) or Pick's disease (PiD).	[75]	
CSF exosomes	pTau-181	Diagnose AD: pTau-181 in CSF exosomes are ↑ in AD vs non-AD controls.	[69]	
AD plasma exosomes	20 differentially expressed miRs	Diagnose AD: 20 miRs were differentially expressed in AD vs matched HC (23b-3p, 24-3p, 29b-3p, 125b-5p, 138-5p, 139-5p, 141-3p, 150-5p, 152-3p, 185-5p, 338-3p, 342-3p, 342-5p, 548 at-5p, 659-5p, 3065-5p, 3613-3p, 3916, 4772-3p, 5001-3p)	[68]	
AD platelet-poor plasma EVs	MOG, miRs (Let-7g-5p, 126-3p, 142-3p, 146a-5p, 223-3p)	Monitor disease progression: 1) ↑ MOG in AD vs controls, which correlated with disease severity/dementia level as assessed by MMSE score. 2) ↓ miRs (Let-7g-5p, 126-3p, 142-3p, 146a-5p, 223-3p) in AD vs Controls, which inversely correlated with disease severity/dementia level as assessed by MMSE score.	[73]	
EVs from postmortem AD blood	fibrinogen proteins (FGG, FGA, FGB), complement C6, peroxiredoxin 2, phosphatidylethanolamine-binding protein 1, peroxiredoxin 2, carboxypeptidase N subunit 2, pigment epithelium-derived factor, fatty acid binding protein 1, serine protease inhibitor 10	Distinguish sporadic AD from controls: 1) Blood microvesicles (100–1000 nm) are increased in AD vs controls. 2) fibrinogen proteins (FGG, FGA, FGB), complement C6, peroxiredoxin 2, phosphatidylethanolamine-binding protein 1, peroxiredoxin 2, carboxypeptidase N subunit 2, pigment epithelium-derived factor, fatty acid binding protein 1 and serine protease inhibitor 10 distinguished sporadic AD from control.	[63]	
	EV Source	Target	Effect/Finding	Reference	
Therapeutics	Human adipose-derived MSC EVs	neuroprotective and neurogenic genes and proteins	Ameliorate neurologic damage and increase neurogenesis in APP/PS1 mouse model for AD: Decreased Aβ deposition, reduced microglia activation, rescue memory deficits.	[97]	
Rat bone marrow-derived MSC EVs (BM-MSC-EVs) containing miR-29c-3p	BACE1	Ameliorate AD pathology: 1) AD rats injected intracerebrally with BM-MSC-EVs containing miR-29c-3p had ↓ cognitive impairment (as assessed by the Morris water maze test), ↓ Aβ deposition, ↓ inflammatory cytokines (IL-1β, IL-6, TNF-α), and ↑ Aβ-degrading enzymes (NEP, IDE). 2) BM-MSC-EVs containing miR-29c-3p blocked BACE1 expression and activated Wnt/β-catenin pathway.	[98]	
Human bone marrow-derived MSC (hBM-MSC) small EVs	Aβ and astrocyte activation	Ameliorate AD pathology: 5XFAD AD mice given hBM-MSC EVs intranasally showed improved cognition, ↓ Aβ plaque load in hippocampus, and ↓ colocalization of GFAP and Thioflavin S, suggesting reduction of astrocyte activation surrounding plaques.	[84]	
Wharton's jelly (human umbilical cord connective tissue) MSC exosomes	Aβ, synaptic plasticity genes (BdnfIV, SYP, GluR, GRIN2B)	Improve cognitive and memory deficits and ameliorate AD pathology: Reduced Aβ plaque burden, inhibited astrocyte activation, and upregulated memory- and synapse-related genes in AD transgenic mouse model.	[99]	
Human neural stem cell (hNSC)-derived EVs	targets of miRs (125b-5p, 124-3p, 125a-5p)	Ameliorate AD pathology: 5xFAD transgenic AD mice intravenously injected with hNSC-EVs had improved cognition (assessed by behavioral testing), ↓ synaptic loss (↑ synaptophysin expression), ↓ Aβ plaque, and ↓ microglial activation/CD68 expression. 2) hNSC-EVs contained miR-125b-5p, miR-124-3p and miR-125a-5p.	[100]	
Engineered mouse bone marrow-derived dendritic cell exosomes containing BACE1 siRNA	BACE1, Aβ42	Reduce BACE1 mRNA and protein in wildtype mouse brains: Intravenous injection of exosomes from immature murine dendritic cells loaded with siRNA for BACE1, a protein implicated in AD, led to targeted reduction of BACE1 and Aβ42 proteins in cortical tissue.	[81]	
Engineered human umbilical cord-derived MSC (UMSC) EVs containing neprilysin (NEP) gene	Aβ cleavage	Reduce Aβ plaque burden, increase neurogenesis and promote anti-inflammation: Compared to Aβ42-injected AD mice with unmodified UMSCs, mice injected with NEP gene-containing UMSCs had EVs in brains that 1) contained more NEP and less BACE1 proteins, 2) had fewer neuritic plaques, and 3) showed greater neurogenic and anti-inflammatory properties (↑ BDNF, ↑ NeuN, ↓ GFAP, ↓ Iba-1) in hippocampus.	[82]	
Engineered mouse macrophage RAW264.7 cell exosomes exogenously loaded with curcumin	block Tau phosphorylation by activating AKT/GSK-3β pathway	Reduce neuronal cell death and cognitive impairment in AD mouse model (okadaic acid injection into mouse brains): Reduced okadaic acid-induced neuronal cell death in hippocampus and reduced cognitive impairment as measured by the Morris water maze test.	[77]	
Abbreviations: aMCI:amnestic mild cognitive impairment;APP:amyloid precursor protein;BACE1:beta-site amyloid precursor protein cleaving enzyme type 1 (β-secretase 1);BDNF:brain-derived neurotrophic factor;FTH1:ferritin heavy chain-1;GFAP:glial fibrillary acidic protein;HSF-1:heat shock factor 1;Iba-1:ionized calcium-binding adaptor molecule 1;IDE:insulin degrading enzyme;IRS:insulin receptor substrate;LAMP 1:lysosome-associated membrane protein 1;MAC:membrane attack complex;MMSE:Mini Mental State Exam;MOG:myelin oligodendrocyte glycoprotein;MSCs:mesenchymal stem cells;NeuN:neuronal nuclear protein;NEP:neprilysin;P-serine-IRS-1:phospho-serine-type I insulin receptor substrate;P-tyrosine-IRS-1:phospho-tyrosine-type I insulin receptor substrate;PAR-4,prostate apoptosis response 4;PHF1:pSer396/pSer404 Tau;pIRS-1:phosphorylated insulin receptor substrate 1;PS1:presenilin 1;P2RY12:purinergic receptor P2Y12;REST:repressor element 1-silencing transcription factor;TMEM119:transmembrane protein 119;TREM2: triggering receptor expressed on myeloid cells 2.

EV biomarkers in MS and AD

Access to pathologically relevant tissues is extremely difficult for neurological diseases. Because EVs are released from disease-relevant cells into accessible biofluids and they can cross the BBB-carrying cell- and disease-specific molecular signatures, they are an attractive source for biomarkers in diagnosing, monitoring and treatment of disease. As a form of “liquid biopsy”, EVs may be preferable over biofluids because they not only offer a protective shell for possibly sensitive biomolecules, but there is also a lower probability of contaminants and irrelevant molecules being present. Furthermore, EVs immunopurified from specific cell types may have an even lower contaminant burden and higher relevant cargo. Most of the biomolecules put forth as potential biomarkers for MS and AD are miRs and proteins that have been found in EVs isolated from the blood and CSF [Table 2, Table 3]. The source of EVs can originate from a variety of cell types. Although it is frequently the case that an increase in EV number is associated with disease, it is often not known the precise cargo of the EVs and how the various biomolecules they contain affect disease.

For MS, the quantity of EVs in the plasma and CSF has been shown to be increased in MS patients compared to HCs as well as increased cell type-specific EVs have been identified [14,27,[46], [47], [48]]. Furthermore, EV numbers may be increased during the exacerbation vs remission phase of the disease [15,46,49]. In some instances, the EV cargo was interrogated and some biomarkers were identified which can differentiate one clinical form of disease from another. For example, a set of nine miRs (miR-15b-5p, miR-23a-3p, miR-223-3p, miR-374a-5p, miR-30b-5p, miR-433-3p, miR-485-3p, miR-342-3p, miR-432-5p) were identified in serum exosomes that were upregulated in RRMS and distinguished it from SPMS with 80% accuracy [50]. Myelin basic protein (MBP) in serum oligodendrocyte EVs was recently identified as being upregulated in MS patients vs HCs with MBP levels being highest in PPMS, followed by RRMS, and then CIS [51]. Because Epstein-Barr virus (EBV) is a risk factor for AD, EBV proteins in serum exosomes from MS patients have also been investigated with results showing not only are the EBV proteins EBNA1, LMP1 and LMP2A increased in RRMS vs HCs, but their levels are higher in active vs stable disease [52].

For AD biomarkers, much of the focus has centered on finding Aβ and Tau, the components of the characteristic hallmarks of AD, in EVs isolated from blood or CSF that are derived from different cell types. Neurons [34,41,[53], [54], [55]], astrocytes [43] and microglia [36,42,56] have all been shown to release EVs containing Aβ or Tau that participate in AD neurodegeneration. In addition to Aβ and Tau, other cargo has been identified in EVs released by CNS cells that participate in AD-associated pathologies such as synaptic impairment [57], inflammation [[58], [59], [60]], lysosomal dysfunction [61], BBB disruption [62,63], and insulin resistance [55,64]. Due to overlapping pathomechanisms, sometimes the same molecular EV cargo has been identified in both AD and MS as being potential biomarkers (e.g., c1q, fibrinogen, miR-342-3p). Like MS, the number of exosomes/EVs released in AD may be higher during pathologic conditions [56,62,63]. This may be a result of endolysosomal dysfunction that pushes unwanted molecules towards the endocytic pathway where they are disposed of in the form of exosomes [65]. In addition to the detection of disease [[66], [67], [68], [69]], specific EV cargo has also been identified that can distinguish between different types of AD [63] as well as monitor the progression of disease [61,[70], [71], [72], [73], [74]]. Moreover, the detection of preclinical AD as early as 10 years prior to clinical diagnosis of manifest AD has been reported using plasma neuronal EV biomarkers [64], and frontotemporal dementia may be differentiated from AD by differences in plasma neuronal EV cargo [70]. Because changes in Tau are associated with other neurological diseases, it has also been suggested that EVs may serve as biomarkers of AD-specific tauopathy since EVs found in brain fluids of AD patients carry different pathological Tau species that distinguish them from other tauopathies, such as Pick's disease and progressive supranuclear palsy, which display morphologically different types of Tau aggregates [75].

EV therapeutics in MS and AD

Being natural products of the body, exosomes/EVs are less immunogenic. Along with their ability to transport cargo across the BBB, it is no wonder that exosomes/EVs are being explored as possible therapeutic vehicles. One therapeutic approach stems from the observation that EV release is increased during pathology. Thus, blocking EV secretion is one possible avenue. Indeed, it was shown that intraperitoneal injection of the pharmacologic drug GW4869, which targets neutral sphingomyelinase 2, into 5XFAD mouse brains decreased levels of brain exosomes, ceramides and Aβ42 plaque [35]. Another approach is through the harvesting of EVs from in vitro cell cultures of mesenchymal stem cells (MSCs) which contain therapeutic cargo that attenuate disease through a variety of mechanisms including reducing inflammation, inducing myelination, decreasing Aβ42, blocking Tau phosphorylation, and augmenting synaptic plasticity [Table 2, Table 3]. A third approach is the modification of naive EVs through exogenous loading of therapeutic agent by co-incubation, sonication, electroporation or transient permeabilization. Examples of exogenous cargo loaded into EVs which have shown promise as therapeutics for MS and AD include curcumin [76,77], resveratrol [78], plasmid expressing IL-4 anti-inflammatory cytokine [79], lentiviral particles containing miR-219a-5p [80], β-secretase (BACE1) siRNA [81], and plasmid expressing neprilysin, an enzyme which cleaves Aβ [82].

Since EVs can cross the BBB, they can be administered by intravenous, intraperitoneal, subcutaneous or intranasal delivery to treat CNS diseases. In addition, studies have shown they can be successfully administered both systemically and locally to provide a therapeutic effect at a desired location [83]. To improve the targeted delivery of exosomes for the treatment of CNS diseases, a specific ligand/receptor or antibody/antigen binding strategy is often used to promote the coupling of exosomes to target cells, thereby facilitating internalization. For AD, intranasal administration has shown promise in animal models [84] and there is currently a human clinical trial registered to test the efficacy of allogeneic adipose tissue-derived MSC exosomes administered by nasal drip (NCT04388982). Due to their potential as biomarkers, treatment and drug delivery vehicles, clinical trials of EVs have accelerated in the past 3 years, in large part due to interest and funding for COVID-19 disease. Despite this recent growth, the EV therapeutic field is still at a very early stage. Most studies are in early phases without a single completed phase III clinical trial.

Limitations, closing remarks and future prospective

Despite the explosion of interest and research in the past decade, the EV field is still in its infancy and its application to CNS diseases is rapidly growing. Evidence to date suggests a very promising potential for EVs to be biomarkers and therapeutics for MS and AD. Nevertheless, some intellectual and technical barriers must be overcome before EVs can be applied to patients. Among the intellectual barriers is the insufficient knowledge about which cells may be the most useful for producing EVs and how best to load EVs with therapeutic molecules. On the technical side, EV isolation in high yield and high purity while preserving their intact structure and biological activity is a very big challenge currently. Moreover, due to the heterogeneity of EVs, standardization in isolation and characterization is sorely needed to enable comparison between laboratories to more accurately assess EV function. The lack of standardization may be one reason why reproducibility across laboratories, thus far, is poor with sometimes conflicting results being reported. With technological advances continuing to be developed, it is the hope that someday the power of EVs can be harnessed to facilitate targeted drug delivery to specific CNS cells to combat neuroinflammation and neurodegeneration to ameliorate MS, AD and other CNS diseases.

Conflicts of interest

The author declares no financial or personal conflicts of interest. Due to space limitations, not all original research findings were included and references to more generalized information were excluded.

Acknowledgments

The author thanks Drs. Lynn Pulliam and Benjamin Zeitlin for critical reading of the manuscript.

Peer review under responsibility of Chang Gung University.
==== Refs
References

1 Walton C King R Rechtman L Kaye W Leray E Marrie RA Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS third edition Mult Scler 26 14 2020 1816 1821 33174475
2 Organization WH Dementia. World Health Organization Newsroom Fact Sheet https://www.who.int/news-room/fact-sheets/detail/dementia
3 Raposo G Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends J Cell Biol 200 4 2013 373 383 23420871
4 Mathieu M Martin-Jaular L Lavieu G Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication Nat Cell Biol 21 1 2019 9 17 30602770
5 Chen W Wang R Li D Zuo C Wen P Liu H Comprehensive analysis of the glycome and glycoproteome of bovine milk-derived exosomes J Agric Food Chem 68 45 2020 12692 12701 33137256
6 Théry C Witwer KW Aikawa E Alcaraz MJ Anderson JD Andriantsitohaina R Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines J Extracell Vesicles 7 1 2018 1535750
7 Budnik V Ruiz-Cañada C Wendler F. Extracellular vesicles round off communication in the nervous system Nat Rev Neurosci 17 3 2016 160 172 26891626
8 Thompson AG Gray E Heman-Ackah SM Mäger I Talbot K Andaloussi SE Extracellular vesicles in neurodegenerative disease — pathogenesis to biomarkers Nat Rev Neurol 12 6 2016 346 357 27174238
9 Schnatz A Müller C Brahmer A Krämer-Albers E-M. Extracellular Vesicles in neural cell interaction and CNS homeostasis FASEB BioAdvances 3 8 2021 577 592 34377954
10 Buzas EI. The roles of extracellular vesicles in the immune system Nat Rev Immunol 23 4 2023 236 250 35927511
11 Delpech JC Herron S Botros MB Ikezu T. Neuroimmune crosstalk through extracellular vesicles in health and disease Trends Neurosci 42 5 2019 361 372 30926143
12 Du C Liu C Kang J Zhao G Ye Z Huang S MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis Nat Immunol 10 12 2009 1252 1259 19838199
13 Azimi M Ghabaee M Naser Moghadasi A Izad M. Altered expression of miR-326 in T cell-derived exosomes of patients with relapsing-remitting multiple sclerosis Iran J Allergy, Asthma Immunol 18 1 2019 108 113 30848579
14 Minagar A Jy W Jimenez JJ Sheremata WA Mauro LM Mao WW Elevated plasma endothelial microparticles in multiple sclerosis Neurology 56 10 2001 1319 1324 11376181
15 Jy W Minagar A Jimenez JJ Sheremata WA Mauro LM Horstman LL Endothelial microparticles (EMP) bind and activate monocytes: elevated EMP-monocyte conjugates in multiple sclerosis Front Biosci : J Vis Literacy 9 2004 3137 3144
16 Jimenez JJ Jy W Mauro LM Horstman LL Ahn ER Ahn YS Elevated endothelial microparticle—monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-β1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes Multiple Sclerosis Journal 11 3 2005 310 315 15957513
17 Sarkar A Mitra S Mehta S Raices R Wewers MD. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1 PLoS One 4 9 2009 e7140
18 Jain RW Yong VW. B cells in central nervous system disease: diversity, locations and pathophysiology Nat Rev Immunol 22 8 2022 513 524 34903877
19 Benjamins JA Nedelkoska L Touil H Stemmer PM Carruthers NJ Jena BP Exosome-enriched fractions from MS B cells induce oligodendrocyte death Neurol Neuroimmunol Neuroinflam 6 3 2019 e550
20 Ryu JK Petersen MA Murray SG Baeten KM Meyer-Franke A Chan JP Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation Nat Commun 6 2015 8164 26353940
21 Willis CM Nicaise AM Menoret A Ryu JK Mendiola AS Mendiola AS Extracellular vesicle fibrinogen induces encephalitogenic CD8+ T cells in a mouse model of multiple sclerosis Proc Natl Acad Sci U S A 116 21 2019 10488 10493 31068461
22 Kempuraj D Thangavel R Natteru P Selvakumar G Saeed D Zahoor H Neuroinflammation induces neurodegeneration J Neurol Neurosurg Spine 1 1 2016 1003 28127589
23 Lassmann H van Horssen J. The molecular basis of neurodegeneration in multiple sclerosis FEBS Lett 585 23 2011 3715 3723 21854776
24 Sbai O Ould-Yahoui A Ferhat L Gueye Y Bernard A Charrat E Differential vesicular distribution and trafficking of MMP-2, MMP-9, and their inhibitors in astrocytes Glia 58 3 2010 344 366 19780201
25 Bianco F Pravettoni E Colombo A Schenk U Möller T Matteoli M Astrocyte-derived ATP induces vesicle shedding and IL-1β release from Microglia1 J Immunol 174 11 2005 7268 7277 15905573
26 Qu Y Ramachandra L Mohr S Franchi L Harding CV Nunez G P2X7 receptor-stimulated secretion of MHC class II-containing exosomes requires the ASC/NLRP3 inflammasome but is independent of caspase-1 J Immunol (Baltimore, Md: 1950) 182 8 2009 5052 5062
27 Verderio C Muzio L Turola E Bergami A Novellino L Ruffini F Myeloid microvesicles are a marker and therapeutic target for neuroinflammation Ann Neurol 72 4 2012 610 624 23109155
28 Zamboni S D’Ambrosio A Margutti P. Extracellular vesicles as contributors in the pathogenesis of multiple sclerosis Multiple sclerosis and related disorders 71 2023 104554 36842311
29 Zhao LN Long HW Mu Y Chew LY. The toxicity of amyloid β oligomers Int J Mol Sci 13 6 2012 7303 7327 22837695
30 John A Reddy PH. Synaptic basis of Alzheimer’s disease: focus on synaptic amyloid beta, P-tau and mitochondria Ageing Res Rev 65 2021 101208 33157321
31 Goedert M. NEURODEGENERATION. Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein Science (New York, NY) 349 6248 2015 1255555
32 Heneka MT Carson MJ El Khoury J Landreth GE Brosseron F Feinstein DL Neuroinflammation in Alzheimer’s disease Lancet Neurol 14 4 2015 388 405 25792098
33 Takahashi RH Milner TA Li F Nam EE Edgar MA Yamaguchi H Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology Am J Pathol 161 5 2002 1869 1879 12414533
34 Rajendran L Honsho M Zahn TR Keller P Geiger KD Verkade P Alzheimer’s disease beta-amyloid peptides are released in association with exosomes Proc Natl Acad Sci U S A 103 30 2006 11172 11177 16837572
35 Dinkins MB Dasgupta S Wang G Zhu G Bieberich E. Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer’s disease Neurobiol Aging 35 8 2014 1792 1800 24650793
36 Joshi P Turola E Ruiz A Bergami A Libera DD Benussi L Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles Cell Death Differ 21 4 2014 582 593 24336048
37 Yuyama K Sun H Mitsutake S Igarashi Y. Sphingolipid-modulated exosome secretion promotes clearance of amyloid-β by microglia J Biol Chem 287 14 2012 10977 10989 22303002
38 Yuyama K Sun H Sakai S Mitsutake S Okada M Tahara H Decreased amyloid-β pathologies by intracerebral loading of glycosphingolipid-enriched exosomes in Alzheimer model mice J Biol Chem 289 35 2014 24488 24498 25037226
39 Yuyama K Sun H Usuki S Sakai S Hanamatsu H Mioka T A potential function for neuronal exosomes: sequestering intracerebral amyloid-β peptide FEBS Lett 589 1 2015 84 88 25436414
40 An K Klyubin I Kim Y Jung JH Mably AJ O’Dowd ST Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo Mol Brain 6 2013 47 24284042
41 Winston CN Goetzl EJ Akers JC Carter BS Rockenstein EM Galasko D Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile Alzheimer’s Dementia 3 2016 63 72
42 Asai H Ikezu S Tsunoda S Medalla M Luebke J Haydar T Depletion of microglia and inhibition of exosome synthesis halt tau propagation Nat Neurosci 18 11 2015 1584 1593 26436904
43 Chiarini A Armato U Gardenal E Gui L Dal Prà I Amyloid β-exposed human astrocytes overproduce phospho-tau and overrelease it within exosomes, effects suppressed by calcilytic NPS 2143—further implications for alzheimer’s therapy Front Neurosci 11 2017 217 28473749
44 Richetin K Steullet P Pachoud M Perbet R Parietti E Maheswaran M Tau accumulation in astrocytes of the dentate gyrus induces neuronal dysfunction and memory deficits in Alzheimer’s disease Nat Neurosci 23 12 2020 1567 1579 33169029
45 Gomes P Tzouanou F Skolariki K Vamvaka-Iakovou A Noguera-Ortiz C Tsirtsaki K Extracellular vesicles and Alzheimer’s disease in the novel era of Precision Medicine: implications for disease progression, diagnosis and treatment Exp Neurol 358 2022 114183 35952764
46 Mazzucco M Mannheim W Shetty SV Linden JR. CNS endothelial derived extracellular vesicles are biomarkers of active disease in multiple sclerosis Fluids Barriers CNS 19 1 2022 13 35135557
47 Marcos-Ramiro B Oliva Nacarino P Serrano-Pertierra E Blanco-Gelaz MA Weksler BB Romero IA Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function BMC Neurosci 15 2014 110 25242463
48 Blandford SN Fudge NJ Corkum CP Moore CS. Analysis of plasma using flow cytometry reveals increased immune cell-derived extracellular vesicles in untreated relapsing-remitting multiple sclerosis Front Immunol 13 2022 803921 35392085
49 Geraci F Ragonese P Barreca MM Aliotta E Mazzola MA Realmuto S Differences in intercellular communication during clinical relapse and gadolinium-enhanced MRI in patients with relapsing remitting multiple sclerosis: a study of the composition of extracellular vesicles in cerebrospinal fluid Front Cell Neurosci 12 2018 418 30498433
50 Ebrahimkhani S Vafaee F Young PE Hur SSJ Hawke S Devenney E Exosomal microRNA signatures in multiple sclerosis reflect disease status Sci Rep 7 1 2017 14293 29084979
51 Agliardi C Guerini FR Zanzottera M Bolognesi E Picciolini S Caputo D Myelin basic protein in oligodendrocyte-derived extracellular vesicles as a diagnostic and prognostic biomarker in multiple sclerosis: a pilot study Int J Mol Sci 24 1 2023 894 36614334
52 Mrad MF Saba ES Nakib L Khoury SJ. Exosomes from subjects with multiple sclerosis express EBV-derived proteins and activate monocyte-derived macrophages Neurol Neuroimmunol Neuroinflam 8 4 2021 e1004
53 Fiandaca MS Kapogiannis D Mapstone M Boxer A Eitan E Schwartz JB Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study Alzheimer’s Dementia 11 6 2015 600 607 e1
54 Sardar Sinha M Ansell-Schultz A Civitelli L Hildesjö C Larsson M Lannfelt L Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers Acta Neuropathol 136 1 2018 41 56 29934873
55 Kapogiannis D Mustapic M Shardell MD Berkowitz ST Diehl TC Spangler RD Association of extracellular vesicle biomarkers with alzheimer disease in the Baltimore longitudinal study of aging JAMA Neurol 76 11 2019 1340 1351 31305918
56 Clayton K. Delpech J.C. Herron S. Iwahara N. Ericsson M. Saito T. Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model Mol Neurodegener 16 1 2021 18 33752701
57 Gabrielli M Prada I Joshi P Falcicchia C D’Arrigo G Rutigliano G Microglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimer’s disease Brain : J Neurol 145 8 2022 2849 2868
58 Goetzl EJ Schwartz JB Abner EL Jicha GA Kapogiannis D. High complement levels in astrocyte-derived exosomes of Alzheimer disease Ann Neurol 83 3 2018 544 552 29406582
59 Nogueras-Ortiz CJ Mahairaki V Delgado-Peraza F Das D Avgerinos K Eren E Astrocyte- and neuron-derived extracellular vesicles from alzheimer’s disease patients effect complement-mediated neurotoxicity Cells 9 7 2020 1618 32635578
60 Gao G Zhao S Xia X Li C Li C Ji C Glutaminase C regulates microglial activation and pro-inflammatory exosome release: relevance to the pathogenesis of alzheimer’s disease Front Cell Neurosci 13 2019 264 31316350
61 Goetzl EJ Boxer A Schwartz JB Abner EL Petersen RC Miller BL Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease Neurology 85 1 2015 40 47 26062630
62 González-Molina LA Villar-Vesga J Henao-Restrepo J Villegas A Lopera F Cardona-Gómez GP Extracellular vesicles from 3xTg-AD mouse and alzheimer’s disease patient astrocytes impair neuroglial and vascular components Front Aging Neurosci 13 2021 593927 33679370
63 Villar-Vesga J Henao-Restrepo J Voshart DC Aguillon D Villegas A Castaño D Differential profile of systemic extracellular vesicles from sporadic and familial alzheimer’s disease leads to neuroglial and endothelial cell degeneration Front Aging Neurosci 12 2020 587989 33281599
64 Kapogiannis D Boxer A Schwartz JB Abner EL Biragyn A Masharani U Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer’s disease Faseb J: Off Publ Federation of American Societies for Experimental Biology 29 2 2015 589 596
65 Miranda AM Lasiecka ZM Xu Y Neufeld J Shahriar S Simoes S Neuronal lysosomal dysfunction releases exosomes harboring APP C-terminal fragments and unique lipid signatures Nat Commun 9 1 2018 291 29348617
66 Cohn W Melnik M Huang C Teter B Chandra S Zhu C Multi-omics analysis of microglial extracellular vesicles from human alzheimer’s disease brain tissue reveals disease-associated signatures Front Pharmacol 12 2021 766082 34925024
67 You Y Muraoka S Jedrychowski MP Hu J McQuade AK Young-Pearse T Human neural cell type-specific extracellular vesicle proteome defines disease-related molecules associated with activated astrocytes in Alzheimer’s disease brain J Extracell Vesicles 11 1 2022 e12183
68 Lugli G Cohen AM Bennett DA Shah RC Fields CJ Hernandez AG Plasma exosomal miRNAs in persons with and without alzheimer disease: altered expression and prospects for biomarkers PLoS One 10 10 2015 e0139233
69 Saman S Kim W Raya M Visnick Y Miro S Saman S Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease J Biol Chem 287 6 2012 3842 3849 22057275
70 Goetzl EJ Boxer A Schwartz JB Abner EL Petersen RC Miller BL Low neural exosomal levels of cellular survival factors in Alzheimer’s disease Annals of Clinical and Translational Neurology 2 7 2015 769 773 26273689
71 Goetzl EJ Abner EL Jicha GA Kapogiannis D Schwartz JB. Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer’s disease Faseb J: Official Publication Of The Federation Of American Societies For Experimental Biology 32 2 2018 888 893
72 Winston CN Goetzl EJ Schwartz JB Elahi FM Rissman RA. Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer’s disease dementia Alzheimer’s Dementia 11 2019 61 66
73 Aharon A Spector P Ahmad RS Horrany N Sabbach A Brenner B Extracellular vesicles of alzheimer’s disease patients as a biomarker for disease progression Mol Neurobiol 57 10 2020 4156 4169 32676990
74 Jia L Zhu M Kong C Pang Y Zhang H Qiu Q Blood neuro-exosomal synaptic proteins predict Alzheimer’s disease at the asymptomatic stage Alzheimer’s Dementia : the journal of the Alzheimer’s Association 17 1 2021 49 60
75 Leroux E Perbet R Caillierez R Richetin K Lieger S Espourteille J Extracellular vesicles: major actors of heterogeneity in tau spreading among human tauopathies Mol Ther : the journal of the American Society of Gene Therapy 30 2 2022 782 797
76 Zhuang X Xiang X Grizzle W Sun D Zhang S Axtell RC Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain Mol Ther : the journal of the American Society of Gene Therapy 19 10 2011 1769 1779
77 Wang H Sui H Zheng Y Jiang Y Shi Y Liang J Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT/GSK-3β pathway Nanoscale 11 15 2019 7481 7496 30942233
78 Zheng X Sun K Liu Y Yin X Zhu H Yu F Resveratrol-loaded macrophage exosomes alleviate multiple sclerosis through targeting microglia J Contr Release 353 2023 675 684
79 Casella G Colombo F Finardi A Descamps H Ill-Raga G Spinelli A Extracellular vesicles containing IL-4 modulate neuroinflammation in a mouse model of multiple sclerosis Mol Ther : the journal of the American Society of Gene Therapy 26 9 2018 2107 2118
80 Osorio-Querejeta I Carregal-Romero S Ayerdi-Izquierdo A Mäger I NL A Wood M MiR-219a-5p enriched extracellular vesicles induce OPC differentiation and EAE improvement more efficiently than liposomes and polymeric nanoparticles Pharmaceutics 12 2 2020 186 32098213
81 Alvarez-Erviti L Seow Y Yin H Betts C Lakhal S Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat Biotechnol 29 4 2011 341 345 21423189
82 Jeong H Kim OJ Oh SH Lee S Reum Lee HA Lee KO Extracellular vesicles released from neprilysin gene-modified human umbilical cord-derived mesenchymal stem cell enhance therapeutic effects in an alzheimer’s disease animal model Stem Cell Int 2021 2021 5548630
83 Sanz-Ros J Mas-Bargues C Romero-García N Huete-Acevedo J Dromant M Borrás C Extracellular vesicles as therapeutic resources in the clinical environment Int J Mol Sci 24 3 2023 2344 36768664
84 Cone AS Yuan X Sun L Duke LC Vreones MP Carrier AN Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer’s disease-like phenotypes in a preclinical mouse model Theranostics 11 17 2021 8129 8142 34373732
85 Aiello A Giannessi F Percario ZA Affabris E. An emerging interplay between extracellular vesicles and cytokines Cytokine Growth Factor Rev 51 2020 49 60 31874738
86 Kimura K Hohjoh H Fukuoka M Sato W Oki S Tomi C Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis Nat Commun 9 1 2018 17 29295981
87 Bhargava P Nogueras-Ortiz C Kim S Delgado-Peraza F Calabresi PA Kapogiannis D. Synaptic and complement markers in extracellular vesicles in multiple sclerosis Mult Scler 27 4 2021 509 518 32669030
88 Galazka G Mycko MP Selmaj I Raine CS Selmaj KW. Multiple sclerosis: serum-derived exosomes express myelin proteins Multiple Sclerosis Journal 24 4 2017 449 458 28273783
89 Selmaj I Cichalewska M Namiecinska M Galazka G Horzelski W Selmaj KW Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis Ann Neurol 81 5 2017 703 717 28411393
90 Laso-García F Ramos-Cejudo J Carrillo-Salinas FJ Otero-Ortega L Feliú A Gómez-de Frutos M Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis PLoS One 13 9 2018 e0202590
91 Riazifar M Mohammadi MR Pone EJ Yeri A Lässer C Segaliny AI Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders ACS Nano 13 6 2019 6670 6688 31117376
92 Li Z Liu F He X Yang X Shan F Feng J. Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia Int Immunopharm 67 2019 268 280
93 Clark K Zhang S Barthe S Kumar P Pivetti C Kreutzberg N Placental mesenchymal stem cell-derived extracellular vesicles promote myelin regeneration in an animal model of multiple sclerosis Cells 8 12 2019 1497 31771176
94 Ahmadvand Koohsari S Absalan A Azadi D. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles attenuate experimental autoimmune encephalomyelitis via regulating pro and anti-inflammatory cytokines Sci Rep 11 1 2021 11658 34079033
95 Casella G Rasouli J Boehm A Zhang W Xiao D Ishikawa LLW Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice Sci Transl Med 12 568 2020 eaba0599 33148622
96 Ruan Z Pathak D Venkatesan Kalavai S Yoshii-Kitahara A Muraoka S Bhatt N Alzheimer’s disease brain-derived extracellular vesicles spread tau pathology in interneurons Brain : J Neurol 144 1 2021 288 309
97 Ma X Huang M Zheng M Dai C Song Q Zhang Q ADSCs-derived extracellular vesicles alleviate neuronal damage, promote neurogenesis and rescue memory loss in mice with Alzheimer’s disease J Contr Release : official journal of the Controlled Release Society 327 2020 688 702
98 Sha S Shen X Cao Y Qu L. Mesenchymal stem cells-derived extracellular vesicles ameliorate Alzheimer’s disease in rat models via the microRNA-29c-3p/BACE1 axis and the Wnt/β-catenin pathway Aging 13 11 2021 15285 15306 34086603
99 Chen YA Lu CH Ke CC Chiu SJ Jeng FS Chang CW Mesenchymal stem cell-derived exosomes ameliorate alzheimer’s disease pathology and improve cognitive deficits Biomedicines 9 6 2021 594 34073900
100 Apodaca LA Baddour AAD Garcia C Jr. Alikhani L Giedzinski E Ru N Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimer’s disease Alzheimer’s Res Ther 13 1 2021 57 33676561
